| Objective: Our study was to find a new biological marker associated with the prognosis of lung adenocarcinoma after curative resection and benefit from adjuvant chemotherapy(ACT).Methods:273 clinical information and RNA-Seq expression data were derived from The Cancer Genome Atlas(TCGA)database.Based on the above data set,the MAXSAT function package,Cox regression analysis and KM curve were used to filter out the second classified prognosis gene.Subpopulation Treatment Effect Pattern Plot(STEPP)analysis was used to screen out the genes related to drug efficacy in GSE42127.The relationship between the gene expression and clinicopathological parameters was assessed in the TCGA database.Kaplan-Meier curves were tested with the log-rank test.The prognostic significance was evaluated by cox proportional hazards regression analysis with 1000 bootstraping.“ Kaplan-Meier Plotter ”database analysis was used to provide further validation.Gene Set Enrichment Analysis(GSEA)was performed using high throughput RNA sequencing data in TCGA and functional gene sets derived from molecular signatures database(MSig DB).Results:All the 297 second classified prognosis genes were analyzed by STEEP in GSE42127.The results showed a beneficial effect of paclitaxel combined with carboplatin(PC)regimen ACT in patients with high TMEM213 expression.The expression of TMEM213 gene was significantly correlated with gender(P=0.013).Kaplan-Meier analysis indicated that patients with high TMEM213 expression had significantly longer overall survival(P=0.014,0.027 and 0.000).Multivariate analysis showed TMEM213 to be an independent predictor for improved overall survival of patients(P = 0.01),and the result was confirmed with bootstrapping techniques and on line “ Kaplan-Meier Plotter ” database analysis.Moreover,Enriched pathway analysis indicated that TMEM213 expression is associated with the two gene sets of KEGG＿DRUG＿METABOLISM＿CYTOCHROME＿P450 and KEGG＿ABC＿TRANSPORTERS.Conclusions:Based on bioinformatics analysis we found TMEM213 expression independently predicted better OS for lung adenocarcinoma.Patients in the high TMEM213 group seems to benefit more from ACT with PC regimen but this needs to be further verified. |
